Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
This locus encodes the transforming growth factor (TGF)-beta type III receptor.
Showing 10 out of 152 products:
Human Polyclonal TGFBR3 Primary Antibody for CyTOF, FACS - ABIN4899613
Bandyopadhyay, Zhu, Malik, Kreisberg, Brattain, Sprague, Luo, López-Casillas, Sun: Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. in Oncogene 2002
Show all 7 Pubmed References
Human Polyclonal TGFBR3 Primary Antibody for IHC, IHC (p) - ABIN4359082
Kato, Nicholson, Neiman, Rantalainen, Holmes, Barrett, Uhlén, Nilsson, Spector, Schwenk: Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model. in Proteome science 2011
Show all 3 Pubmed References
Human Monoclonal TGFBR3 Primary Antibody for ELISA, WB - ABIN1724752
Jiang, Liu, Lei, You, Zhou, Zhang: [Defective expression of TGFBR3 gene and its molecular mechanisms in non-small cell lung cancer cell lines]. in Zhongguo fei ai za zhi = Chinese journal of lung cancer 2010
Show all 2 Pubmed References
Human Monoclonal TGFBR3 Primary Antibody for FACS, ELISA - ABIN1724751
Lambert, Huang, Mythreye, Blobe: The type III transforming growth factor-? receptor inhibits proliferation, migration, and adhesion in human myeloma cells. in Molecular biology of the cell 2011
Show all 2 Pubmed References
Human Polyclonal TGFBR3 Primary Antibody for ELISA - ABIN449737
Woszczyk, Gola, Jurzak, Mazurek, Myka?a-Cie?la, Wilczok: Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. in Medical science monitor : international medical journal of experimental and clinical research 2004
Human Polyclonal TGFBR3 Primary Antibody for FACS - ABIN4896383
Reinartz, Finkernagel, Adhikary, Rohnalter, Schumann, Schober, Nockher, Nist, Stiewe, Jansen, Wagner, Müller-Brüsselbach, Müller: A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. in Genome biology 2016
Human Polyclonal TGFBR3 Primary Antibody for FACS - ABIN4896384
Wang, Yu, Sarnaik, Yu, Hall, Morelli, Zhang, Zhao, Weber: Biomarkers on melanoma patient T cells associated with ipilimumab treatment. in Journal of translational medicine 2012
Inhibition of genes for betaglycan and FIBP (show FIBP Antibodies) in granulosa cells in vitro suggests that they inhibit estradiol production in regressing subordinate follicles.
describe a detailed characterization of TbetaRIII expression in lymphocyte subpopulations demonstrating that this co-receptor is significantly expressed in T but not B lymphocytes and among them, preferentially expressed on naive and central memory T cells
TGF-beta (show TGFB1 Antibodies) type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset PE. Endoglin (show ENG Antibodies) was increased in both subtypes.
TGFBR3 and/or MGEA5 (show MGEA5 Antibodies) rearrangements are much more common in hybrid hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas.
opposing functions for the different GAG modifications on TbetaRIII suggesting that Wnt (show WNT2 Antibodies) interactions with the TbetaRIII heparan sulfate chains result in inhibition of Wnt (show WNT2 Antibodies) signaling, likely via Wnt (show WNT2 Antibodies) sequestration, whereas the chondroitin sulfate GAG chains on TbetaRIII promote Wnt3a (show WNT3A Antibodies) signaling.
Results suggest that high expression levels of alpha-inhibin and beta-glycan transcripts in secretory phase endometrium are associated with a lower chance of achieving pregnancy with in vitro fertilization.
Results show decreased TbetaRIII expression with hepatocellullar carcinoma (HCC (show FAM126A Antibodies)) progression leading to the activation of Smad2 (show SMAD2 Antibodies) and suggest that TbetaRIII acts as a suppressive factor in regulating the migration and invasion of HCC (show FAM126A Antibodies), by inhibiting Smad2 (show SMAD2 Antibodies) and Akt (show AKT1 Antibodies) pathways.
Study shows that TbetaRIII expression is significantly decreased in salivary glands adenoid cystic carcinoma (ACC) patients and defines TbetaRIII as a biomarker exerting antitumor action on ACC progression.
No correlation of loss of heterozygosity at the TGFBR3 locus with clinicopathological parameters suggests that allelic imbalance may be an early genetic event during neoplastic transformation of human endometrium.
Study shows that GDF10 (show GDF10 Antibodies) is down-regulated in patients with oral squamous cell carcinoma, and is an independent risk factor for overall survival. Its expression is regulated by TGFBR3 which shares the signaling inhibiting epithelial-mesenchymal transition.
rs1192415 of TGFBR3 is associated with primary open angle glaucoma.
TGFbetaR3 promotes apoptosis of cardiomyocytes via a p38 (show CRK Antibodies) pathway-associated mechanism, and loss of TGFbetaR3 reduces myocardial infarction injury.
BMP2 (show BMP2 Antibodies) also requires Src (show SRC Antibodies) for filamentous actin polymerization in Tgfbr3(-/-) epicardial cells.
Study identified a novel major binding site for TGF-beta (show TGFB1 Antibodies)-like growth factors in TGFR-3. Findings potentially provide novel experimental insight into the general function of zona pellucida domain-containing proteins.
Retinoic acid enhanced TbetaRIII expression and that this increase contributed to LF-stimulated IgA (show IgA Antibodies) production.
Pro-fibrotic cardiac effect of miR (show MLXIP Antibodies)-328 was mediated by down-regulating TGFbR3 and up-regulating TGFb1 (show TGFB1 Antibodies).
These data demonstrate that TbetaRIII regulates BMP-mediated signaling and biological effects, primarily through the ligand sequestration effects of sTbetaRIII in normal and cancerous mammary epithelial cells.
Glucocorticoids recruit Tgfbr3 and Smad1 (show SMAD1 Antibodies) to shift transforming growth factor-beta signaling from the Tgfbr1 (show TGFBR1 Antibodies)/Smad2 (show SMAD2 Antibodies)/3 axis to the Acvrl1 (show ACVRL1 Antibodies)/Smad1 (show SMAD1 Antibodies) axis in lung fibroblasts.
work reveals a 'seed and soil' mechanism where TGF-beta2 (show TGFB2 Antibodies) and TGF-beta (show TGFB1 Antibodies)-RIII signalling through p38alpha (show MAPK14 Antibodies)/beta regulates DTC dormancy and defines restrictive (BM) and permissive (lung) microenvironments for HNSCC metastasis
TGFBR3 mediated suppression of cancer progression includes effects on the tumor immune microenvironment.
This study provides evidence that the expressions of inhibin alpha subunit (show INHA Antibodies) and betaglycan are inferior in cystic follicles, and this may be caused by the decrease in FSH (show BRD2 Antibodies) in the presence of a cystic follicle.
This locus encodes the transforming growth factor (TGF)-beta type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.
transforming growth factor, beta receptor III
, transforming growth factor, beta receptor III (betaglycan, 300kDa)
, transforming growth factor beta receptor type 3-like
, TGF-beta receptor type 3
, TGF-beta receptor type III
, betaglycan proteoglycan
, transforming growth factor beta receptor type 3
, transforming growth factor, beta receptor 3
, TGF-beta type III receptor
, transforming growth factor beta receptor III
, transforming growth factor-beta type III receptor